Table 3.
Baseline 5HIAA as predictor for CSS, PFS
| SSA single | SSA combined | IFN | PRRT | |||||
|---|---|---|---|---|---|---|---|---|
| HR [95% CI] | p | HR [95% CI] | p | HR [95% CI] | p | HR [95% CI] | p | |
| CSS | ||||||||
| N = 75 | N = 48 | N = 26 | N = 92 | |||||
| Continuous | 1.014 [0.989;1.040] | 0.26 | 1.014 [1.002;1.026] | 0.02 | 1.064 [1.013;1.119] | 0.01 | 1.071 [1.038;1.104] | <0.01 |
| 5–10× | 0.07 | 0.02 | 0.17 | 0.01 | ||||
| 5–10× | 2.50 [0.98;6.36] | 0.38 [0.09;1.69] | 1.35 [0.27;6.73] | 2.08 [1.04;4.15] | ||||
| >10 | 2.03 [0.92;4.45] | 2.01 [0.96;4.21] | 3.19 [0.90;11.39] | 2.60 [1.39;4.85] | ||||
| >2 | 1.62 [0.79;3.31] | 0.18 | 1.37 [0.59;3.18] | 0.47 | 1.08 [0.35;3.33] | 0.89 | 1.49 [0.73;3.06] | 0.27 |
| >5 | 2.18* [1.10;4.34] | 0.02 | 1.33 [0.65;2.72] | 0.43 | 2.20 [0.71;6.84] | 0.16 | 2.36* [1.34;4.17] | <0.01 |
| >10 | 1.70 [0.81;3.60] | 0.16 | 2.42*** [1.18;4.94] | 0.01 | 2.98* [0.89;9.97] | 0.06 | 1.97 [1.15;3.38] | 0.01 |
| >Optimal: treatment | 2.54*** [1.25;5.18] | 0.01 | 1.08 [0.51;2.30] | 0.84 | 3.89*** [1.22;12.40] | 0.01 | 6.30*** [3.24;12.27] | <0.01 |
| >Optimal | 1.98 [1.00;3.95] | 0.05 | 1.50 [0.73;3.06] | 0.26 | 2.63 [0.83;8.32] | 0.09 | 2.57 [1.48;4.46] | <0.01 |
| PFS | ||||||||
| N = 75 | N = 45 | N = 26 | N = 92 | |||||
| Continuous | 1.003 [0.985;1.022] | 0.74 | 1.001 [0.985;1.017] | 0.90 | 1.026 [0.986;1.067] | 0.21 | 1.048 [1.012;1.087] | 0.01 |
| 5–10x | 0.05 | 0.40 | 0.26 | 0.01 | ||||
| 5–10x | 2.54 [1.16;5.55] | 1.15 [0.41;3.22] | 3.03 [0.74;12.45] | 3.06 [1.46;6.40] | ||||
| >10 | 1.33 [0.72;2.46] | 1.65 [0.79;3.44] | 1.88 [0.47;7.61] | 1.97 [0.99;3.95] | ||||
| >2 | 1.64* [0.95;2.81] | 0.07 | 1.29 [0.56;2.99] | 0.54 | 1.69 [0.52;5.54] | 0.38 | 1.86 [0.73;4.74] | 0.19 |
| >5 | 1.59 [0.93;2.72] | 0.09 | 1.49 [0.74;2.97] | 0.26 | 2.32* [0.74;7.27] | 0.14 | 2.34*** [1.26;4.36] | 0.01 |
| >10 | 1.17 [0.65;2.12] | 0.60 | 1.59*** [0.80;3.15] | 0.18 | 1.46 [0.39;5.46] | 0.57 | 1.30 [0.72;2.34] | 0.39 |
| >Optimal: treatment | 2.08*** [1.11;3.90] | 0.02 | 1.35 [0.63;2.91] | 0.43 | 2.53*** [0.75;8.54] | 0.12 | 2.34*** [1.26;4.36] | 0.01 |
| >Optimal | 1.55 [0.90;2.65] | 0.11 | 1.49 [0.74;2.97] | 0.26 | 1.63 [0.49;5.46] | 0.42 | 2.34*** [1.26;4.36] | 0.01 |
Prognostic value of baseline 5-hydroxyindoleacetic acid (5HIAA) for cancer-specific (CSS) and progression-free survival (PFS) given as continuous values, at cut-offs 2×, 5×, 10 × ULN and at “optimal” estimated cut-offs for the whole cohort (optimal) and per treatment given (optimal: treatment). Significant p values are marked in bold numbers. Hazard ratios providing best discrimination are marked with *** (all cut-offs) and with * for “standard” cut-offs
ULN upper limit of normal, SSA somatostatin analogues, IFN Interferon-alpha, PRRT peptide receptor radionuclide therapy